Align Summit 2026: Calluna Pharma has a S100A4 (a DAMP) targeting program currently in phase 2 for IPF that will read out in Q1 2027
CEO Mark Gaffney walks us through the idea of targeting a DAMP and, in this case, S100A4 specifically, and describes the differentiated profile Calluna hopes to see compared to currently marketed therapies for IPF.
Coverage brought to you by










.png)